On March 19, 2025, Oxford BioTherapeutics announced a multiyear collaboration with Roche (SWX: ROG, OTCMKTS: RHHBY) to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer. This partnership leverages Oxford BioTherapeutics’ innovative discovery platform to identify and validate new targets for cancer therapies.
OGAP-Verify Discovery Platform
Oxford BioTherapeutics’ recently launched enhanced proprietary OGAP-Verify discovery platform offers greater sensitivity, enabling the selection of targets with improved attributes for drug development. This platform will be instrumental in identifying promising targets for further research.
Collaboration Details
Under the terms of the agreement, targets identified via the OGAP-Verify platform will be validated through the research collaboration. Roche will lead any further research, development, and commercialization efforts against these targets. Oxford BioTherapeutics will receive up to US$36 million in upfront payments from Roche and may be eligible for milestone payments potentially exceeding US$1 billion, along with product royalties on net sales.-Fineline Info & Tech
Leave a Reply